Trazimab as a new promising approach to treat invasive Aspergillosis

Takis is proud to announce very promising results achieved with Trazimab, a monoclonal antibody against a new target expressed by Aspergillus fumigatus, a fungus which causes Aspergillosis, a rare and deadly disease.


There has been in increase in the number of projects for the development of biotech drugs against infections caused by the fungus Aspergillus: that is a promising field of research, with Takis company at the forefront. This is thanks to an experienced team of researchers who are dedicated to identifying new molecular targets against which to develop the drugs of the future. The next goal for Takis is the production of Trazimab, a monoclonal antibody for the treatment of Aspergillus infections. The new therapeutic approach could prove to be effective in particular against invasive pulmonary aspergillosis, a respiratory infection that is affecting more and more people around the world and for which current drugs are likely to be inadequate.

Among the infections caused by fungi of the genus Aspergillus, invasive aspergillosis is perhaps the most relevant, with 200,000 cases per year worldwide and a mortality rate that despite treatments remains between 25% and 80%. Whereas it does not affect immunocompetent individuals, invasive aspergillosis is extremely dangerous, even lethal for immunocompromised individuals.


There are many immunosuppressed patients, for example those taking immunosuppressive drugs following a transplant or those undergoing chemotherapy or radiotherapy to treat cancer. For these people, the only hope of treatment, until recently, were antifungal drugs, in particular azoles. But they are no longer enough, because of the onset of multi-resistant strains both in clinical settings and in the environment due to the abuse of fungicide in agriculture. They are increasingly widespread and require the development of innovative therapeutic strategies.
The hope against Aspergillus fumigatus today comes from biotechnology. Within the Trazimab project funded by the Campania region, Takis is developing biotechnological drugs against Aspergillus, such as monoclonal antibodies. This represents a potential alternative to traditional therapy, which in addition to dealing with the widespread phenomenon of drug-resistance, is also associated with important side effects on the kidneys and liver. Thanks to decades of experience in the production of antibodies and in vivo studies, the Takis team aims to transform the treatment of invasive aspergillosis with an innovative antibody, directed against a still unexplored molecular target, which promises to open a new way in the fight against Aspergillus.
Monoclonal antibodies are today one of the most avant-garde therapeutic approaches for the treatment of cancer, but their use is beginning to extend also to infectious diseases. This is thanks to their ability to recognize specific molecular targets with extreme precision, reducing side effects and maximizing efficacy. “We believe that the development of Trazimab could be a great opportunity for the use of monoclonal antibodies for a disease, such as Invasive Pulmonary Aspergillosis, in which small molecules still represent the gold standard” said Emanuele Marra, Director of Infectious diseases at Takis,“I also consider that the methodology used for the development of this antibody could facilitate the production of specific antibodies against fungal proteins and not just saccharide components”

2 December 2019 - Takis second Biotech in Europe at EIT Health Catapult Final!

Takis second Biotech in Europe at EIT Health Catapult Final!

Takis second Biotech in Europe at EIT Health Catapult Final

Paris, 2 December, 2019 – NeoMatrix, a neoantigen-based cancer vaccine based on Precision Immunology has been awarded second among the best Biotech companies in Europe. The journey started this summer, when a though selection of 150 companies led to a list of 7 finalists.

“The EIT Health Catapult competition was a great experience and most importantly validated NeoMatrix concept and business model” said Dr. Fabio Palombo, Director of NeoMatrix. “We have all the tools to make our dream real: provide new cures to cancer patients.”

“This is an fantastic recognition of our work and our ideas” said Luigi Aurisicchio, CEO/CSO. “We are more and more motivated to move forward NeoMatrix to clinical trial. In Paris we had the opportunity to meet many other stakeholders, learn each other and above all to establish a great network for future collaborations. ”
Are you ready to be "catapulted" in the Future of Cancer Therapy?

For more information please see our NeoMatrix web page

Check out all EHC finalists at: FINALISTS EHC 2019 – BIOTECH HEALTH Category

2-3 December 2019 - PARIS - European EIT Health Biotech Final: Forza Takis and Forza Italia!

NeoMatrix Personalized Cancer Vaccine Program at EIT Health Final in Paris, 2-3 December 2019


Takis among the 7 European Finalists at EIT Health Summit

Paris, 2 December, 2019 – Takis, an Italian Biotech Company leader in Gene Therapy, Cancer Vaccines and generation of monoclonal antibodies is proud to announce its participation at the

eit Healt Summit 2019

the place where collective ideas transform the future of healthcare.

Takis S.R.L. will present NeoMatrix, a neoantigen-based cancer vaccine, as a proof-of-concept of personalized immunology. NeoMatrix starts from tumor biopsy  and gets to the manufacturing of a personalized cancer vaccine in 5 weeks.

“We are proud to have been selected among the finalists in this important European competition. Not only as Takis Biotech, but also as the only Italian company among incredible companies with brilliant ideas and teams able to create new opportunities for patients” said Luigi Aurisicchio, CEO/CSO.

“We know that immune system has a key role in fighting cancer” said Dr. Fabio Palombo, Leader and Champion of NeoMatrix. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide precision therapies to human patients able to complement current standard of care.”

Stay tuned for the competition!


For more information please see our NeoMatrix web page

Check out all EHC finalists at: FINALISTS EHC 2019

Hamburg, Germany – November 13-15 Engage with Takis Biotech at BIO-EUROPE 2019

TDr Luigi Aurisicchio, CEO/CSO at Takis and Evvivax, will attend Bioeurope 2019. As Europe's largest life science partnering conference, BIO-Europe offers countless opportunities to engage with global life science partners. As key biotech, Takis will discuss with potential partners a number of available opportunities and services. The event brings together makers and investors within the life science industry to debate and to drive forward leading innovation.

This is an excellent opportunity to discuss Takis pipeline in one-to-one network meetings. Book your meeting with Luigi now!

To learn more:

26 September 2019 - Genomics and personalized medicine. Takis, the Italian excellence in biotechnology, challenges Europe!

The company of the Tecnopolo di Castel Romano in Rome is among the 7 finalists of the European Health Catapult. The final will be held on 2 and 3 December in Paris.

26 September, ROME - Takis with its advanced projects presented a personalized therapeutic vaccine against cancer at the European Health Catapult Initiative earning its place in the final. A result achieved thanks to the creation of a personalized therapeutic vaccine against cancer. It is therefore a new challenge that aims at personalized medicine, genomics and cellular therapies that many people see as a necessary path on which to invest.

The genome of each tumor, in fact, presents mutations that differ from patient to patient and generate abnormal proteins called neo-antigens, absent in healthy cells. The vaccine designed by Takis instructs the cells of the immune system to recognize tumor neo-antigens and to destroy only the cells that express them. But since every tumor is different, each patient needs a tailored therapy: the starting point is the sequencing of the tumor genome, which helps the researchers to build an ad hoc vaccine.

This is an innovative project, which Takis researchers are pursuing with competence and enthusiasm. And that at European Health Catapult, in which 42 start-ups participated in Europe, has already captured the interest of investors, confirming once again the excellence of Italian research in the oncology field.

"We are proud of this result - said Luigi Aurisicchio, CEO of Takis -. In recent years we have undertaken many projects and we have dedicated ourselves to developing increasingly targeted and effective therapies against cancer. The merit is, above all, of our researchers, who put passion into what we do day after day to help patients in oncology ".

Fabio Palombo, head of the research program, is of the same opinion: "Thanks to the growing knowledge in Immuno-Oncology, to the Next Generation Sequencing and to ever more effective technologies, it is now possible to think of approaches to personalized medicine inconceivable until a few years ago. And we Italians with our ideas and our imagination, we can make a huge contribution to this constantly evolving field ".

With his experience in innovative cancer therapies, Takis is the only Italian company to have achieved this goal, proving to be among the 7 best biotech companies in Europe. Thanks to an intense research activity, which has succeeded in intercepting the most advanced topics in the fight against cancer in recent years. Such as immunotherapy, which uses the immune system to fight cancer, giving life to potentially more effective therapies than traditional ones, and above all more targeted. The scientific production of Takis, in fact, appears to be increasingly oriented towards the future, which is that of precision medicine and tailored to the patient. A possibility that today, thanks to in-depth knowledge of the human genome, is becoming more and more concrete.


LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal Models

STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse models demonstrated their ability to eliminate tumors in vivo, and to potentially prevent initial occurrence.

Evvivax S.R.L. designed a synthetic gene sequence to produce immunity in companion animals, directed against the protein telomerase (TERT), which is overexpressed in 85% of all mammalian cancers, whereas Takis S.R.L. designed a neoantigen-based cancer vaccine (TK), as a proof-of-concept of personalized immunology. For the studies, the TERT and TK based vaccines were produced in linear DNA form by LineaRx. Here is a summary of the recently completed studies performed in vivo:

Previous results from Phase 1 of the collaboration’s Joint Development Agreement (JDA) confirmed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase. The results reported herein are from the Phase 2 of the JDA using mice implanted with murine colon cancer.
In the prophylactic use of the telomerase vaccine, wherein vaccination is done before addition of tumor cell lines to the mice, transplanted tumors were cleared within 10 days.
In the therapeutic application using either TERT or TK linear DNA vaccine application, cancer cells were introduced and allowed to grow before administration of the vaccine. The successful reduction of total tumor mass was accomplished in conjunction with antibodies that targeted PD-1 and CTLA4. These antibodies, known as Checkpoint Inhibitors, are commonly used in oncology strategies that rely upon immunotherapy. In this setting the tumor cells were reduced significantly within 30 days.
The strategy of the Takis TK neoantigen vaccine uses unique multiple-target antigenic epitopes that have been identified from the tumor of a human patient. The linear DNA can utilize the genes for several of the most effective universal antigens such as TERT, or neoantigens that are more personalized to the patient.

“We know that immune system has a key role in fighting cancer” said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide new therapies to our pet friends and human patients.”

For more information please see the Press Release from Applied DNA Sciences adnas